Copyright
©The Author(s) 2022.
World J Diabetes. Jul 15, 2022; 13(7): 532-542
Published online Jul 15, 2022. doi: 10.4239/wjd.v13.i7.532
Published online Jul 15, 2022. doi: 10.4239/wjd.v13.i7.532
Table 2 Comparison of estimated values of best corrected visual acuity, intraocular pressure between the two groups (mean ± SD)
| Groups | BCVA (LogMAR) | IOP (mmHg) | ||||
| Before treatment | 1 mo after treatment | 3 mo after treatment | Before treatment | 1 mo after treatment | 3 mo after treatment | |
| Compaq group (n = 48) | 0.78 ± 0.12 | 0.72 ± 0.13 | 0.51 ± 0.10 | 16.84 ± 2.77 | 16.40 ± 2.81 | 16.39 ± 2.64 |
| Ranibizumab group (n = 48) | 0.80 ± 0.11 | 0.75 ± 0.14 | 0.57 ± 0.13 | 16.50 ± 2.80 | 16.72 ± 2.76 | 16.81 ± 2.82 |
| t value | -0.851 | -1.088 | -2.535 | 0.598 | -0.563 | -0.753 |
| P value | 0.397 | 0.279 | 0.013 | 0.551 | 0.575 | 0.453 |
- Citation: Li YF, Ren Q, Sun CH, Li L, Lian HD, Sun RX, Su X, Yu H. Efficacy and mechanism of anti-vascular endothelial growth factor drugs for diabetic macular edema patients. World J Diabetes 2022; 13(7): 532-542
- URL: https://www.wjgnet.com/1948-9358/full/v13/i7/532.htm
- DOI: https://dx.doi.org/10.4239/wjd.v13.i7.532